Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an update.
NeuroSense Therapeutics Ltd. has announced the completion of its 18-month Phase 2b PARADIGM study, showing PrimeC’s potential in slowing ALS disease progression by 33% and enhancing survival rates. The company received positive feedback from the FDA and is on track to start a Phase 3 study in mid-2025. NeuroSense is also preparing for early commercialization in Canada, aiming for a potential launch in 2026. Financially, NeuroSense has strengthened its position with a $5 million private placement, ensuring compliance with Nasdaq’s equity requirements and supporting ongoing clinical developments.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a late-stage clinical biotechnology company focused on developing novel treatments for severe neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company is actively working on PrimeC, a promising treatment aimed at slowing disease progression and improving survival rates in ALS patients.
YTD Price Performance: 39.74%
Average Trading Volume: 213,213
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $25.21M
See more insights into NRSN stock on TipRanks’ Stock Analysis page.
Trending Articles
- Apple and Nvidia Partner to Enable Faster LLM Token Generation
- Amazon Faces Largest Teamsters Strike to Date in Busy Christmas Season
- ‘Time to Move to the Sidelines,’ Says Analyst About Rivian Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
